REGENXBIO Inc.
Graf
Godt at vide: Investering i aktier giver typisk et positivt afkast på lang sigt, men indebærer også risiko. Du kan miste dele af eller hele din investering. Tidligere data for denne aktie er ikke en pålidelig indikator for fremtidige afkast. Data fra eksterne udbydere er ikke blevet ændret af Saxo Bank. Se fuld ansvarsfraskrivelse for data.
Om REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
/ 